Conduct%20Early-Phase%20(I/II)%20Clinical%20Trials
Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024-05-01;202114024. doi: 10.1016/j.ejca.2024.114024. PubMed PMID: 38513383.
Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024-04-20;JCO2301428. doi: 10.1200/JCO.23.01428. PubMed PMID: 38335467.
Butrovich MA, Qin J, Xue X, Ivy SP, Nolin TD, Beumer JH. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. PubMed PMID: 38307411; PMCID: PMC10939791.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024-03-26;JCO2301544. doi: 10.1200/JCO.23.01544. PubMed PMID: 38531002.
Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024-03-20;JCO2301994. doi: 10.1200/JCO.23.01994. PubMed PMID: 38194616; PMCID: PMC10950161.
You KL, Sereika SM, Bender CM, Hamilton JB, Mazanec SR, Brufsky A, Rosenzweig MQ. Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer: the association of social determinants of health and neighborhood socioeconomic disadvantage. Support Care Cancer. 2024-03-12;32(4):224. doi: 10.1007/s00520-024-08429-y. PubMed PMID: 38472437.
Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024-03-01; doi: 10.1002/ajh.27212. PubMed PMID: 38258329.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024-02-20; doi: 10.1158/1078-0432.CCR-23-1977. PubMed PMID: 38376912.
Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024-01-23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. PubMed PMID: 38113141.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024-01-12;OF1-OF14. doi: 10.1158/2159-8290.CD-23-0964. PubMed PMID: 37861461; PMCID: PMC10784743.
Beumer JH, Salamone SJ. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. PubMed PMID: 38178775; PMCID: PMC10783536.
Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024-01-01;196113434. doi: 10.1016/j.ejca.2023.113434. PubMed PMID: 38008031.
Im A, Pusic I, Onstad L, Kitko CL, Hamilton BK, Alousi AM, Flowers ME, Sarantopoulos S, Carpenter P, White J, Arai S, El Jurdi N, Chen G, Cutler C, Lee S, Pidala J. Patient-reported treatment response in chronic graft-versus-host disease. Haematologica. 2024-01-01; doi: 10.3324/haematol.2023.282734. PubMed PMID: 37226713; PMCID: PMC10772515.
Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Wade JL, McCarron EC, Swain SM, Wolmark N. Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer. J Natl Cancer Inst. 2023-11-08; doi: 10.1093/jnci/djad078. PubMed PMID: 37184928; PMCID: PMC10637036.
Puthanmadhom Narayanan S, Ren D, Oesterreich S, Lee AV, Rosenzweig MQ, Brufsky AM. Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer. NPJ Breast Cancer. 2023-11-01;9(1):90. doi: 10.1038/s41523-023-00595-2. PubMed PMID: 37914742; PMCID: PMC10620133.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023-07-10;41(20):3565-3575. doi: 10.1200/JCO.22.02570. PubMed PMID: 37406456.
Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023-02-16;29(4):723-730. doi: 10.1158/1078-0432.CCR-22-1768. PubMed PMID: 36595540.
Atiya HI, Frisbie L, Goldfeld E, Orellana T, Donnellan N, Modugno F, Calderon M, Watkins S, Zhang R, Elishaev E, Soong TR, Vlad A, Coffman L. Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. Cancer Res. 2022-12-16;82(24):4680-4693. doi: 10.1158/0008-5472.CAN-22-1294. PubMed PMID: 36219681; PMCID: PMC9755968.
Carleton N, McAuliffe PF. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022-12-01;19(12):745-746. doi: 10.1038/s41571-022-00684-4. PubMed PMID: 36042383; PMCID: PMC9675711.
Beumer JH, Chu E, Salamone SJ. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. PubMed PMID: 36264552; PMCID: PMC9772116.
Vyas A, Gomez-Casal R, Cruz-Rangel S, Villanueva H, Sikora AG, Rajagopalan P, Basu D, Pacheco J, Hammond GRV, Kiselyov K, Duvvuri U. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy. Proc Natl Acad Sci U S A. 2022-03-22;119(12):e2100670119. doi: 10.1073/pnas.2100670119. PubMed PMID: 35286200; PMCID: PMC8944912.
Diamantopoulos LN, Appleman LJ. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022-03-01;23(3):e99. doi: 10.1016/S1470-2045(22)00086-9. PubMed PMID: 35240100.
Vyas A, Harbison RA, Faden DL, Kubik M, Palmer D, Zhang Q, Osmanbeyoglu HU, Kiselyov K, Méndez E, Duvvuri U. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021-11-15;27(22):6250-6264. doi: 10.1158/1078-0432.CCR-20-4789. PubMed PMID: 34407971; PMCID: PMC8611487.
Gomez Marti JL, Nasrazadani A, Brufsky AM. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021-08-01;70103489. doi: 10.1016/j.ebiom.2021.103489. PubMed PMID: 34280778; PMCID: PMC8318981.
Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021-07-20;39(21):2367-2374. doi: 10.1200/JCO.20.02824. PubMed PMID: 33739848; PMCID: PMC8462554.
Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021-07-01;71(4):287-298. doi: 10.3322/caac.21663. PubMed PMID: 33784415.
Bender CM, Sereika SM, Gentry AL, Duquette JE, Casillo FE, Marsland A, Brufsky AM, Evans S, Gorantla VC, Grahovac TL, McAuliffe PF, Steiman JG, Zhu Y, Erickson KI. Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. Support Care Cancer. 2021-07-01;29(7):3743-3752. doi: 10.1007/s00520-020-05865-4. PubMed PMID: 33210238; PMCID: PMC8131400.
Namburi S, Broxmeyer HE, Hong CS, Whiteside TL, Boyiadzis M. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. PubMed PMID: 33139859; PMCID: PMC10165724.
Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021-06-01;16(6):1017-1029. doi: 10.1016/j.jtho.2021.02.010. PubMed PMID: 33676017.
Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, Uversky VN, Lundstrom K, Adadi P, Palù G, Aljabali AAA, Chauhan G, Kandimalla R, Tambuwala MM, Lal A, Abd El-Aziz TM, Sherchan S, Barh D, Redwan EM, Bazan NG, Mishra YK, Uhal BD, Brufsky A. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano. 2021-05-25;15(5):8069-8086. doi: 10.1021/acsnano.1c00629. PubMed PMID: 33826850.
Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021-05-01;39(13):1507-1508. doi: 10.1200/JCO.20.03477. PubMed PMID: 33630658.
Gomez Marti JL, Wells A, Brufsky AM. Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. J Med Virol. 2021-04-01;93(4):2396-2405. doi: 10.1002/jmv.26743. PubMed PMID: 33331649; PMCID: PMC9553089.
Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol. 2021-04-01;18(4):252-268. doi: 10.1038/s41575-020-00386-1. PubMed PMID: 33335282; PMCID: PMC9106093.
Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021-04-01;4(4):e216322. doi: 10.1001/jamanetworkopen.2021.6322. PubMed PMID: 33856473; PMCID: PMC8050744.
Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. PubMed PMID: 32814841.
Seyran M, Pizzol D, Adadi P, El-Aziz TMA, Hassan SS, Soares A, Kandimalla R, Lundstrom K, Tambuwala M, Aljabali AAA, Lal A, Azad GK, Choudhury PP, Uversky VN, Sherchan SP, Uhal BD, Rezaei N, Brufsky AM. Questions concerning the proximal origin of SARS-CoV-2. J Med Virol. 2021-03-01;93(3):1204-1206. doi: 10.1002/jmv.26478. PubMed PMID: 32880995; PMCID: PMC7898912.
Brewer J, Gomez Marti JL, Brufsky A. Potential interventions for SARS-CoV-2 infections: Zinc showing promise. J Med Virol. 2021-03-01;93(3):1201-1203. doi: 10.1002/jmv.26523. PubMed PMID: 32940918.
Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021-01-20;39(3):254-255. doi: 10.1200/JCO.20.02963. PubMed PMID: 33332192.
Appleman LJ. Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. J Natl Cancer Inst. 2021-01-04;113(1):7-8. doi: 10.1093/jnci/djaa077. PubMed PMID: 32516413; PMCID: PMC7781442.
Ling DC, Moppins BL, Champ CE, Gorantla VC, Beriwal S. Quality of Regional Nodal Irradiation Plans in Breast Cancer Patients Across a Large Network-Can We Translate Results From Randomized Trials Into the Clinic? Pract Radiat Oncol. 2021-01-01;11(1):e30-e35. doi: 10.1016/j.prro.2020.06.007. PubMed PMID: 32615162.
Brufsky A, Lotze MT. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. J Med Virol. 2020-11-01;92(11):2379-2380. doi: 10.1002/jmv.26067. PubMed PMID: 32458475; PMCID: PMC7283725.
Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. PubMed PMID: 33077513; PMCID: PMC7574947.
Brufsky A. Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. J Med Virol. 2020-09-01;92(9):1386-1390. doi: 10.1002/jmv.25902. PubMed PMID: 32311094; PMCID: PMC7264516.
Brufsky A, Lotze MT. DC/L-SIGNs of hope in the COVID-19 pandemic. J Med Virol. 2020-09-01;92(9):1396-1398. doi: 10.1002/jmv.25980. PubMed PMID: 32374430; PMCID: PMC7267543.
Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020-08-15;26(16):4233-4241. doi: 10.1158/1078-0432.CCR-20-0152. PubMed PMID: 32371537; PMCID: PMC7724952.
Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol. 2020-07-01;92(7):770-775. doi: 10.1002/jmv.25887. PubMed PMID: 32293710; PMCID: PMC7262330.
Brufsky A, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? J Natl Cancer Inst. 2020-07-01;112(7):659-660. doi: 10.1093/jnci/djz216. PubMed PMID: 31693134; PMCID: PMC7357314.
Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020-06-01;80(9):883-892. doi: 10.1007/s40265-020-01320-0. PubMed PMID: 32436070; PMCID: PMC8579493.
Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020-03-01;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. PubMed PMID: 32035019.
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020-02-10;38(5):444-453. doi: 10.1200/JCO.19.01455. PubMed PMID: 31821109; PMCID: PMC7007289.
Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019-12-14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. PubMed PMID: 31813636; PMCID: PMC7199428.
Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019-10-01;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. PubMed PMID: 31308059; PMCID: PMC6820348.
Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019-10-01;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. PubMed PMID: 31494036.
Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019-08-01;466-7. doi: 10.1016/j.ebiom.2019.07.073. PubMed PMID: 31378696; PMCID: PMC6712046.
Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019-06-01;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. PubMed PMID: 30836094.
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Mäenpää J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019-04-01;145(1):129-135. doi: 10.1002/ijgo.12749. PubMed PMID: 30656645.
Clump DA, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019-03-01;25(5):1441-1442. doi: 10.1158/1078-0432.CCR-18-3078. PubMed PMID: 30413524; PMCID: PMC6415532.
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019-01-01;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. PubMed PMID: 30509771; PMCID: PMC6691732.
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. PubMed PMID: 30514386; PMCID: PMC6278156.
Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018-09-15;78(18):5398-5407. doi: 10.1158/0008-5472.CAN-18-0316. PubMed PMID: 30042150; PMCID: PMC6139073.
Garcia CA, Dacic S, Villaruz LC. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018-08-01;13(8):e135-e136. doi: 10.1016/j.jtho.2018.02.031. PubMed PMID: 30049372.
Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018-05-14;6(1):35. doi: 10.1186/s40425-018-0342-x. PubMed PMID: 29754585; PMCID: PMC5950135.
Branstetter BF 4th. The Future of Radiology. JAMA. 2017-12-05;318(21):2141. doi: 10.1001/jama.2017.16659. PubMed PMID: 29209714.
Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res. 2017-12-01;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. PubMed PMID: 28899969; PMCID: PMC5898434.
Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017-09-01;5922-32. doi: 10.1016/j.ctrv.2017.06.004. PubMed PMID: 28719836.
Mathew A, Brufsky A. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017-07-01;18(7):843-845. doi: 10.1016/S1470-2045(17)30437-0. PubMed PMID: 28677561.
Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017-05-01;15(5):555-562. doi: 10.6004/jnccn.2017.0058. PubMed PMID: 28476735.
Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017-04-24;10(1):94. doi: 10.1186/s13045-017-0453-8. PubMed PMID: 28434396; PMCID: PMC5402171.
Mathew A, Brufsky A. Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncol. 2017-04-01;18(4):428-429. doi: 10.1016/S1470-2045(17)30150-X. PubMed PMID: 28238596.
Lee D, Leroy C, Crevant C, Bonhomme-Coury L, Babonneau F, Laurencin D, Bonhomme C, De Paëpe G. Interfacial Ca(2+) environments in nanocrystalline apatites revealed by dynamic nuclear polarization enhanced (43)Ca NMR spectroscopy. Nat Commun. 2017-01-27;814104. doi: 10.1038/ncomms14104. PubMed PMID: 28128197; PMCID: PMC5290151.
Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016-12-20;490. doi: 10.1186/s40425-016-0188-z. PubMed PMID: 28018601; PMCID: PMC5168808.
Sgroi DC, Brufsky A. Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. J Clin Oncol. 2016-11-10;34(32):3941-3942. doi: 10.1200/JCO.2016.67.2949. PubMed PMID: 27551134.
Brufsky AM, Davidson NE. Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation? Clin Cancer Res. 2016-10-15;22(20):4963-4965. doi: 10.1158/1078-0432.CCR-16-1513. PubMed PMID: 27521446; PMCID: PMC5154749.
Brufsky A. Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol. 2016-09-01;17(9):1175-6. doi: 10.1016/S1470-2045(16)30295-9. PubMed PMID: 27501769.
Beumer JH, Tawbi H, Ivy SP. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol. 2016-07-10;34(20):2430-1. doi: 10.1200/JCO.2016.67.2790. PubMed PMID: 27185845.
Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol. 2016-01-10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. PubMed PMID: 26392101; PMCID: PMC4980565.
Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. Lancet. 2015-10-03;386(10001):1319-1320. doi: 10.1016/S0140-6736(15)61163-1. PubMed PMID: 26211825.
Ivy SP, Beumer JH. Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet? JAMA Oncol. 2015-09-01;1(6):732-3. doi: 10.1001/jamaoncol.2015.1926. PubMed PMID: 26181495; PMCID: PMC4696392.
Boyiadzis M, Whiteside TL. Information transfer by exosomes: A new frontier in hematologic malignancies. Blood Rev. 2015-09-01;29(5):281-90. doi: 10.1016/j.blre.2015.01.004. PubMed PMID: 25686749.
Duvvuri U. ANO1 plays a critical role in prostatic hyperplasia. Proc Natl Acad Sci U S A. 2015-08-04;112(31):9506-7. doi: 10.1073/pnas.1512075112. PubMed PMID: 26216998; PMCID: PMC4534251.
Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. Blood Rev. 2015-07-01;29(4):263-8. doi: 10.1016/j.blre.2015.01.002. PubMed PMID: 25631637; PMCID: PMC4494875.
Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015-05-01;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. PubMed PMID: 25348512; PMCID: PMC4411210.
Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. A phase i study of DMS612, a novel bifunctional alkylating agent. Clin Cancer Res. 2015-02-15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. PubMed PMID: 25467180; PMCID: PMC4755291.
Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015-01-15;21(2):286-94. doi: 10.1158/1078-0432.CCR-14-1790. PubMed PMID: 25424847; PMCID: PMC4297523.
Brufsky A. Length of chemotherapy and use of bevacizumab for breast cancer. Lancet Oncol. 2014-11-01;15(12):1285-7. doi: 10.1016/S1470-2045(14)70480-2. PubMed PMID: 25439683.
Quan K, Rajagopalan MS, Heron DE. Stereotactic body radiation therapy is a cost-effective alternative to intensity-modulated radiation therapy. J Clin Oncol. 2014-10-20;32(30):3451. doi: 10.1200/JCO.2014.56.6737. PubMed PMID: 25185091.
Mathew A, Brufsky A. Breast cancer: Zoledronic acid--more than just a bone drug. Nat Rev Clin Oncol. 2014-10-01;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. PubMed PMID: 25200411.
Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, Grandis J, Gaither LA, Puthenveedu MA, Duvvuri U. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clin Cancer Res. 2014-09-01;20(17):4673-88. doi: 10.1158/1078-0432.CCR-14-0363. PubMed PMID: 24919570; PMCID: PMC4160843.
